Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

Market Cap	9.47B
Revenue (ttm)	177.01M
Net Income (ttm)	-1.13B
Shares Out	399.60M
EPS (ttm)	-2.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,569,012
Average Volume	12,731,494
Open	25.02
Previous Close	24.47
Day's Range	23.40 - 25.87
52-Week Range	15.36 - 35.93
Beta	1.01
RSI	60.78
Earnings Date	Aug 29, 2025

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products in China and internationally. The company offers its products for oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection; MAILISHU for the treatment of postmenopausal women with osteoporosis; JUNMAIKANG, an immunological product; and MAIWEIJIAN for giant cell tumor of bone. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,416
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688062

Financial Performance

In 2024, SHA:688062's revenue was 199.78 million, an increase of 56.28% compared to the previous year's 127.84 million. Losses were -1.04 billion, -0.90% less than in 2023.